# CASUALTY GIANT CELL ARTERITIS (GCA) PROTOCOL

| PROFILE |
|-----------------|-----------------|
| REFERENCE NUMBER: | SWBH/Ophth/09 |
| VERSION: | 3 |
| STATUS: | DRAFT |
| ACCOUNTABLE DIRECTOR: | Clinical Director |
| AUTHOR: | Consultant Ophthalmologist |
| DATE OF LAST REVIEW/ ORIGIN DATE: | February 2007 |
| DATE OF THIS REVIEW: | May 2009 |
| APPROVED BY: | Surgery – Divisional Governance Group Drugs and Therapeutic Committee |
| DATE OF APPROVAL | April 2011 |
| IMPLEMENTATION DATE: | April 2011 |
| DATE NEXT REVIEW DUE: | April 2013 |
| REVIEW BODY: | Ophthalmology Team |
| CATEGORISATION: | Ophthalmology |
| DATE OF EQUALITY IMPACT ASSESSMENT: | n/a |
| APPLICATION: | Trust wide |
| PRINCIPAL TARGET AUDIENCE: | Clinicians – Ophthalmology, Emergency Dept, Rheumatology |
| ASSOCIATED TRUST DOCUMENTS: |
Casualty Giant Cell Arteritis (GCA) protocol

1.0 Aim

- To improve accuracy of diagnosis GCA and speed of appropriate treatment
- To provide guidelines concerning critical questions to ask patient, features to seek on examination and core laboratory tests

Guidelines re initial treatment:

This protocol is a guide. Whenever there is uncertainty concerning GCA discuss the patient with a senior doctor (both GCA and high dose systemic steroid therapy for the condition carry risks of adverse events including death\(^{1,2}\)).

The diagnosis of GCA requires intuition and experience to identify atypical presentations and this document cannot substitute for either.

2.0 On arrival at Eye Casualty

If a patient is suspected by the triage nurse of having GCA:

- Inform the senior doctor in the casualty for appropriate prioritisation
- Blood capillary sugar, blood pressure, temperature and urinalysis
- History and examination*
- Investigations as appropriate*
- Diagnosis*
- Action*

*see below

Ophthalmic presentations which are suggestive of GCA are anterior ischaemic optic neuropathy (AION, 88%\(^{18}\)), central retinal arterial occlusion (CRAO, 5%\(^{18}\)), branch retinal arteriolar occlusion (BRAO, 5%\(^{18}\)), transient visual loss (44%\(^{15}\)), choroidal infarction (6%\(^{18}\)) recent cranial nerve palsy.

3.0 History

These are the minimum features which must be documented before deciding upon the diagnosis or otherwise of GCA. See Appendix 1 for guidance concerning history taking.
4.0 Symptoms

Table 1 below allows the clinician to form an impression of pre-test probability by highlighting the most important features to point to a diagnosis of GCA.

Table 1

<table>
<thead>
<tr>
<th>Feature</th>
<th>+ve LR* (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ischaemic:</strong></td>
<td></td>
</tr>
<tr>
<td>Jaw claudication</td>
<td>4.2 (2.8–6.2)</td>
</tr>
<tr>
<td>Diplopia</td>
<td>3.4 (1.3–8.6)</td>
</tr>
<tr>
<td>Temporal headache</td>
<td>1.5 (0.78–3.0)</td>
</tr>
<tr>
<td>Any visual symptom§</td>
<td>1.1 (0.93–1.3)</td>
</tr>
<tr>
<td><strong>Inflammatory response:</strong></td>
<td></td>
</tr>
<tr>
<td>Weight loss</td>
<td>1.3 (1.1–1.5)</td>
</tr>
<tr>
<td>Fever</td>
<td>1.2 (0.98–1.4)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>1.2 (0.96–1.4)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1.2 (0.98–1.4)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>0.93 (0.81–1.1)</td>
</tr>
</tbody>
</table>

§50% have jaw claudication in GCA
§44% have amaurosis which precedes visual loss in GCA
*LR for +ve temporal artery biopsy JAMA. 2002;287:92–101

Screen to check for other reasons for systemic inflammatory response. These conditions if present reduce the risk of GCA being the cause of raised inflammatory markers (and systemic illness) and as such are negative risk factors for GCA:
- Urinary symptoms (frequency, dysuria, acute incontinence etc).
- Respiratory symptoms (cough, SOB etc).
- GI symptoms (diarrhoea, vomiting etc).
- ENT symptoms (sore throat, ear ache etc).
- Recent major surgery
- Known neoplasia
- Recent ischaemic event
  - Mean CRP post MI at ten days and ten weeks; 17.2 mg/l and 4.3 mg/l respectively, ESR at ten days and ten weeks 35.4 mm/hr and 24.3 mm/hr.

5.0 Examination

Full ophthalmic examination including:
- Optic nerve functions
  - Visual acuity
  - Relative afferent pupil defect
  - Ishihara plates
  - Fundal appearance including optic nerve appearance
- Anterior segment examination (including signs of ocular ischaemia: flare, cells, corneal oedema etc)
- Intraocular pressure
- Eye movements (including saccadic velocities)
- Superficial temporal artery. Careful examination is absolutely critical as it yields the most strongly associated signs.

Table 2 allows the clinician to build on the findings from the history to refine the pre-test probability of GCA.

**Table 2**

<table>
<thead>
<tr>
<th>Superficial temporal artery features</th>
<th>+ve Likelihood ratio (LR)* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beaded ie irregular contour</td>
<td>4.6 (1.1–18.4)</td>
</tr>
<tr>
<td>Prominent</td>
<td>4.3 (2.1–8.9)</td>
</tr>
<tr>
<td>Absent pulse</td>
<td>2.7 (0.55–13.4)</td>
</tr>
<tr>
<td>Tender§</td>
<td>2.6 (1.9–3.7)</td>
</tr>
<tr>
<td>Any abnormality</td>
<td>2.0 (0.55–13.4)</td>
</tr>
</tbody>
</table>

*LR for positive TAB, JAMA. 2002;287:92–101
§ Compare to adjacent scalp area not over artery

**6.0 Investigations**

Urgent: Verify that sample leaves department and call biochemistry (ext. 5162) and haematology (ext. 4241) to inform them of sample arrival. Leave your phone number on the blood form.

ESR
CRP
FBC
Blood pressure & Blood Capillary Sugar

### Laboratory parameters

<table>
<thead>
<tr>
<th>Sensitivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESR* &gt;50mm/hr</td>
</tr>
<tr>
<td>CRP&gt;lab ref range (5mg/mL at City Hospital)</td>
</tr>
<tr>
<td>Raised ESR and CRP</td>
</tr>
<tr>
<td>Thrombocytosis§</td>
</tr>
<tr>
<td>Normochromic normocytic anaemia</td>
</tr>
</tbody>
</table>

*upper limit of normal, men: age/2, women: (age +10)/2 (see appendix)
§see appendix

ESR is made lower by the presence of polycythaemia, NSAIDS, steroids, congestive cardiac failure, haemoglobinopathy
ESR is elevated by anaemia, malignancy, infection and inflammation
FBC: increased WCC raises suspicion of infective process/haematological malignancies

**7.0 Diagnosis**

### Diagnostic criteria§

1. Age >50 y
2. New headache
3. Temporal artery abnormality (examination finding)
4. ESR >49 mm/hr
5. Temporal artery biopsy characteristic of GCA

3 or more of these criteria give
sensitivity of 94%  
specificity of 91% for GCA*.

*Amongst a study group of patients with other vasculitides

8.0 Action

If the working diagnosis is GCA URGENT action is indicated.

1) Inform patient and with permission and if possible inform relatives of working diagnosis. Discussion should include:

   a. Risk to second eye of visual loss.  
      Involvement of the other eye occurs in 37% at a mean time of 23 days after the first eye18 (despite steroid treatment).  
      Of all cases of visual loss 94% occur before commencing steroid20.

   b. Visual prognosis for the presenting eye  
      70% 6/60 or worse18  
      Amongst those with visual loss 49% have unchanged vision, vision gets worse in 17%, improved in 34%18.

   c. Risks from steroids including the dangers of sudden cessation, the steroid ‘card’ which patients must carry.

   d. Long term nature of follow up and steroid treatment.  
      Three quarters of patients are on a physiological dose of systemic steroid one year after commencement but about half experience a relapse requiring an increase in steroid dose17.

2) Immediate intravenous steroid treatment to avoid visual loss in second eye (default position should be to administer this in eye casualty) unless contraindicated. If in doubt re contraindications consider physician involvement urgently.

   NB: Treatment should never be delayed by the planning of the TAB

Starting dose:

Pulsed iv 1000 mg methylprednisolone (daily for three days) for any acute cranial ischaemic complication eg AION especially if:

   a) visual loss within 24 hours  
   b) or impending visual symptoms eg amaurosis but no objective optic nerve dysfunction  
   c) or lost vision in second eye

Alternatively:

1–1.5 mg/kg prednisolone orally once daily (first dose stat).
NB evidence shows high dose intravenous therapy (vs oral) allows a faster taper down of corticosteroid\textsuperscript{16}, the visual prognosis in the affected eye is slightly better if treated with iv steroid and the risk to the other eye is less\textsuperscript{18}.

3) \textit{At commencing steroid} start bone-protection and gastro-protection.

- If aged over 65 years commence alendronic acid 70 mg weekly (see Appendix 1)\textsuperscript{22} and adequate vitamin D/calcium supplementation.
- Commence 15–30 mg lansoprazole once daily, especially if co-prescribing aspirin anti-platelet therapy\textsuperscript{23}
- Commence anti-platelet therapy eg. aspirin 75–300 mg/day unless contraindicated
  Retrospective data shows a significant reduction in ischaemic events for GCA patients on anti-platelet therapy\textsuperscript{20}

4) Inform consultant on call and \textit{admit to ward} for monitoring post-prandial blood capillary sugars, 4-hourly blood pressure measurement and evaluation of the need for daily systemic steroid treatment. Consider referral to a team who routinely manage these patients (eg. neuro-ophthalmology).

5) Temporal artery biopsy (TAB).

- Timing: the sooner the better. Aim to do biopsy within 3 days of presentation during routine theatre time unless prevented by conflicting clinical priorities.
  Rates of TAB positivity are no less immediately after starting steroid treatment than before\textsuperscript{8}, are less in week 2 of treatment than week 1\textsuperscript{10} but can demonstrate active arteritis beyond 45 days and ‘healed’ arteritis \textit{averaging 82 days}\textsuperscript{19}. 86\% of biopsies performed after 4 weeks in clinically diagnosed GCA are positive\textsuperscript{24}.
- Necessity: histological diagnosis is required even in the context of a clear clinical syndrome and certainly in cases of diagnostic uncertainty
- Length: harvest \textit{minimum} 12.5 mm\textsuperscript{3-5} \textit{in vivo} artery length. Aim for 20 mm. Measure this with callipers and record artery length in notes and on pathology request form. Longer artery yields greater diagnostic sensitivity.
  Aim to take the abnormal ‘beaded’ section of artery and document that this has been done. If the artery feels and looks normal a longer specimen is needed\textsuperscript{15}.

6) Ensure that the receiving on call team know about the patient to monitor re: disease control, steroid induced side effects, temporal artery biopsy scheduling etc
9.0 References


7. Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA 2002;287(1):92-101


12. A Miller, M Green, D Robinson Simple rule for calculating normal erythrocyte sedimentation rate British medical journal (Clinical research ed)1983 vol. 286 (6361) pp. 266


Appendix 1

1.0 History taking

The history is the most important part of the assessment for GCA. It is critical that facts are gained without leading questions.

Jaw claudication (myogenic) is specifically a pain which worsens with continued forceful chewing cf. arthrogenic pain. Patients sometimes get tongue claudication with talking and eating. This is very specific for GCA.

2.0 ESR

Taking lower values as the threshold for abnormal obviously increases sensitivity for detecting inflammatory conditions.

An alternative formula which lowers threshold (for older patients) and increases sensitivity:

<table>
<thead>
<tr>
<th>Threshold formula</th>
<th>Sensitivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miller\textsuperscript{12} et al.</td>
<td>Men: age/2, Women: (age +10)/2</td>
</tr>
<tr>
<td>Hayreh\textsuperscript{13} et al.</td>
<td>Men: 17.3 + (0.18 x age), Women: 22.1+ (0.18 x age)</td>
</tr>
</tbody>
</table>

3.0 Thrombocytosis

Although the sensitivity of thrombocytosis (platelets$>$400x10$^3$ /l) is lower than raised ESR and CRP values (according to most authors) the specificity, positive predictive value and negative predictive value of thrombocytosis are useful. Thrombocytosis therefore has a greater value than a raised ESR in supporting the diagnosis of GCA (as opposed to ruling it out in the context of normal values)\textsuperscript{14}.

<table>
<thead>
<tr>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Positive predictive value</th>
<th>Negative predictive value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevated ESR</td>
<td>76%</td>
<td>27%</td>
<td>54%</td>
</tr>
<tr>
<td>Platelets$&gt;$400x10$^3$ /l</td>
<td>57%</td>
<td>91%</td>
<td>87%</td>
</tr>
</tbody>
</table>

4.0 Bisphosphonate therapy

The risks are oesophageal ulceration is reduced by appropriate use.

Once weekly dose.

Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medication); patient should stand or sit upright for at least 30 minutes after taking tablet.